Premium
DICER1 syndrome: Approach to testing and management at a large pediatric tertiary care center
Author(s) -
Engelen Kalene,
Villani Anita,
Wasserman Jonathan D.,
Aronoff Laura,
Greer MaryLouise C.,
Tijerin Bueno Marta,
Gallinger Bailey,
Kim Raymond H.,
Grant Ronald,
Meyn M. Stephen,
Malkin David,
Druker Harriet
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26720
Subject(s) - medicine , proband , genetic testing , pediatrics , asymptomatic , retrospective cohort study , tertiary care , mutation , genetics , gene , biology
Abstract Background To expand the current knowledge of DICER1 syndrome and to propose criteria for genetic testing based on experience at a pediatric tertiary care center. Procedure This study involved a retrospective chart review of the 78 patients (47 probands and 31 family members) seen in the Cancer Genetics Program at The Hospital for Sick Children (SickKids) who were offered genetic testing for DICER1 . Results Of 47 probands offered genetic testing for DICER1 , 46 pursued testing: 11 (23.9%) carried a pathogenic variant and one proband (2.1%) carried a missense variant of uncertain significance with evidence for pathogenicity. Thirty‐one family members of variant‐positive probands were offered testing: eight of the 25 who agreed to testing carried their familial variant (32.0%). Overall, 20 patients were identified to have a variant in DICER1 (eight males, 12 females). Of these, 13 (65.0%) presented with clinical manifestations associated with the syndrome. The most common lesions were pleuropulmonary blastoma (PPB) (five of 20 patients, 25.0%) and pineoblastoma (three of 20 patients, 15.0%). The average age at which individuals were diagnosed with a primary neoplasm was 5.2 years (range 0.8–20 years, median 3.0). Surveillance at our institution, with a median follow‐up time of 23 months, has identified PPB in two asymptomatic individuals. These lesions were identified at early stages, thus potentially reducing treatment‐related morbidity and mortality. Conclusion This study further delineates the DICER1 syndrome phenotype and demonstrates the feasibility of a DICER1 syndrome surveillance protocol for the early detection of tumors.